BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 28584138)

  • 21. Initial treatment and outcome of Candida glabrata versus Candida albicans bloodstream infection.
    Klevay MJ; Horn DL; Neofytos D; Pfaller MA; Diekema DJ;
    Diagn Microbiol Infect Dis; 2009 Jun; 64(2):152-7. PubMed ID: 19376667
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Resistance in human pathogenic yeasts and filamentous fungi: prevalence, underlying molecular mechanisms and link to the use of antifungals in humans and the environment.
    Jensen RH
    Dan Med J; 2016 Oct; 63(10):. PubMed ID: 27697142
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Successful treatment of azole-refractory Candida guilliermondii fungemia with a combination therapy of micafungin and liposomal amphotericin B].
    Saitoh T; Matsushima T; Shimizu H; Osaki Y; Yamane A; Irisawa H; Yokohama A; Uchiumi H; Handa H; Tsukamoto N; Karasawa M; Nojima Y; Murakami H
    Rinsho Ketsueki; 2008 Feb; 49(2):94-8. PubMed ID: 18341039
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Posttreatment Antifungal Resistance among Colonizing Candida Isolates in Candidemia Patients: Results from a Systematic Multicenter Study.
    Jensen RH; Johansen HK; Søes LM; Lemming LE; Rosenvinge FS; Nielsen L; Olesen B; Kristensen L; Dzajic E; Astvad KM; Arendrup MC
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1500-8. PubMed ID: 26711776
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Three cases of Candida fermentati fungemia following hematopoietic stem cell transplantation.
    Morita K; Honda A; Koya J; Toyama K; Ikeda M; Misawa Y; Okugawa S; Nakamura F; Moriya K; Kurokawa M
    J Infect Chemother; 2018 Jul; 24(7):576-578. PubMed ID: 29371065
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genomic description of acquired fluconazole- and echinocandin-resistance in patients with serial
    Misas E; Seagle E; Jenkins EN; Rajeev M; Hurst S; Nunnally NS; Bentz ML; Lyman MM; Berkow E; Harrison LH; Schaffner W; Markus TM; Pierce R; Farley MM; Chow NA; Lockhart SR; Litvintseva AP
    J Clin Microbiol; 2024 Feb; 62(2):e0114023. PubMed ID: 38265207
    [No Abstract]   [Full Text] [Related]  

  • 27. Candida glabrata: an emerging pathogen in Brazilian tertiary care hospitals.
    Colombo AL; Garnica M; Aranha Camargo LF; Da Cunha CA; Bandeira AC; Borghi D; Campos T; Senna AL; Valias Didier ME; Dias VC; Nucci M
    Med Mycol; 2013 Jan; 51(1):38-44. PubMed ID: 22762208
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of candidemia with echinocandins: data on hospital resource use from a real world setting.
    Wade RL; Chaudhari P; Campbell RS; Hays HD; Nathanson BH; Yi J; Horn D
    J Med Econ; 2012; 15(6):1130-8. PubMed ID: 22788668
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk factors of mortality and comparative in-vitro efficacy of anidulafungin, caspofungin, and micafungin for candidemia.
    Lee SC; Lee CW; Shih HJ; Huang SH; Chiou MJ; See LC
    J Microbiol Immunol Infect; 2014 Jun; 47(3):245-53. PubMed ID: 24246191
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer.
    Bodey GP; Mardani M; Hanna HA; Boktour M; Abbas J; Girgawy E; Hachem RY; Kontoyiannis DP; Raad II
    Am J Med; 2002 Apr; 112(5):380-5. PubMed ID: 11904112
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination antifungal therapy: where are we now, and where are we going?
    Marr K
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 7):24-9. PubMed ID: 15651179
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epidemiology, risk factor, species distribution, antifungal resistance and outcome of Candidemia at a single French hospital: a 7-year study.
    Tadec L; Talarmin JP; Gastinne T; Bretonnière C; Miegeville M; Le Pape P; Morio F
    Mycoses; 2016 May; 59(5):296-303. PubMed ID: 26806101
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A retrospective Evaluation of fluconazole for the treatment of Candida glabrata fungemia.
    Wilson AG; Micek ST; Ritchie DJ
    Clin Ther; 2005 Aug; 27(8):1228-37. PubMed ID: 16199247
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Candida infections in non-neutropenic children after the neonatal period.
    Hacimustafaoglu M; Celebi S
    Expert Rev Anti Infect Ther; 2011 Oct; 9(10):923-40. PubMed ID: 21973304
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness of echinocandins versus fluconazole for treatment of persistent candidemia: A time-dependent analysis.
    Lin KY; Chen PY; Chuang YC; Wang JT; Sun HY; Sheng WH; Chen YC; Chang SC
    J Infect; 2018 Sep; 77(3):242-248. PubMed ID: 29932963
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emergence of multiple resistance profiles involving azoles, echinocandins and amphotericin B in Candida glabrata isolates from a neutropenia patient with prolonged fungaemia.
    Cho EJ; Shin JH; Kim SH; Kim HK; Park JS; Sung H; Kim MN; Im HJ
    J Antimicrob Chemother; 2015 Apr; 70(4):1268-70. PubMed ID: 25550394
    [No Abstract]   [Full Text] [Related]  

  • 37. Changes in karyotype and azole susceptibility of sequential bloodstream isolates from patients with Candida glabrata candidemia.
    Shin JH; Chae MJ; Song JW; Jung SI; Cho D; Kee SJ; Kim SH; Shin MG; Suh SP; Ryang DW
    J Clin Microbiol; 2007 Aug; 45(8):2385-91. PubMed ID: 17581937
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance.
    Sanguinetti M; Posteraro B; Fiori B; Ranno S; Torelli R; Fadda G
    Antimicrob Agents Chemother; 2005 Feb; 49(2):668-79. PubMed ID: 15673750
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of first-line therapies for the treatment of candidemia in ICU patients: A propensity score analysis.
    Bienvenu AL; Pradat P; Guerin C; Aubrun F; Fellahi JL; Friggeri A; Guichon C; Hernu R; Menotti J; Monard C; Paulus S; Rimmele T; Piriou V; Chidiac C; Argaud L; Leboucher G
    Int J Infect Dis; 2020 Apr; 93():15-21. PubMed ID: 31982622
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Unexpected effects of azole transporter inhibitors on antifungal susceptibility in Candida glabrata and other pathogenic Candida species.
    Nagayoshi Y; Miyazaki T; Shimamura S; Nakayama H; Minematsu A; Yamauchi S; Takazono T; Nakamura S; Yanagihara K; Kohno S; Mukae H; Izumikawa K
    PLoS One; 2017; 12(7):e0180990. PubMed ID: 28700656
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.